Curis Lifesciences Ltd
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
- Market Cap ₹ 77.9 Cr.
- Current Price ₹ 96.4
- High / Low ₹ 148 / 92.6
- Stock P/E 14.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding has decreased over last quarter: -24.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| 35.42 | 35.58 | |
| 32.16 | 27.14 | |
| Operating Profit | 3.26 | 8.44 |
| OPM % | 9.20% | 23.72% |
| 0.34 | 0.31 | |
| Interest | 1.33 | 0.85 |
| Depreciation | 0.73 | 0.68 |
| Profit before tax | 1.54 | 7.22 |
| Tax % | 20.13% | 25.90% |
| 1.23 | 5.36 | |
| EPS in Rs | 24.60 | 107.20 |
| Dividend Payout % | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 336% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Equity Capital | ||
| Reserves | ||
| Total Liabilities | ||
| CWIP | ||
| Investments | ||
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | ||
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | ||
| Working Capital Days | ||
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Jan 2026 | |
|---|---|---|---|
| EBITDA Margin % ・Standalone data |
|
||
| PAT Margin % ・Standalone data |
|||
| Export Ready Products (New Registrations) Number ・Standalone data |
|||
| Domestic Turnover Share % ・Standalone data |
|||
| Export Turnover Share % ・Standalone data |
|||
| Land Size Square Meters ・Standalone data |
|||
| Number of Developed Formulations (Portfolio) Number ・Standalone data |
|||
| Own Brand Export Share in Revenue % ・Standalone data |
|||
| Total Construction Area (Manufacturing Facility) Square Meters ・Standalone data |
|||
Documents
Announcements
-
Investor Presentation
11 March 2026 - Curis Lifesciences uploaded investor presentation to company website on 11 March 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 March 2026 - Cancellation of analyst/investor site visit scheduled February 28, 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
24 February 2026 - Analyst/investor site visit at Curis Sanand plant on February 28, 2026 (physical).
-
Analysts/Institutional Investor Meet/Con. Call Updates
29 January 2026 - Transcript of Jan 22 Valueportal meet: Curis outlines Nigeria JV, IPO-funded expansion; FY25 revenue Rs50.26cr, EBITDA ~21%.
-
Analysts/Institutional Investor Meet/Con. Call Updates
22 January 2026 - Management participated in Valueportal investor interaction on Jan 22, 2026; business overview and strategy discussed.
Annual reports
No data available.
Concalls
-
Mar 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptPPT
-
Jan 2026TranscriptPPT
Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.